Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 9.9.2019 | EN | Official Journal of the European Union | C 305/8 |

---

Judgment of the Court (Fourth Chamber) of 3 July 2019 — Viridis Pharmaceutical Ltd. v European Union Intellectual Property Office (EUIPO), Hecht-Pharma GmbH

(Case C-668/17 P) [(1)](#ntr1-C_2019305EN.01000801-E0001)

(Appeal - European Union trade mark - Revocation proceedings - Word mark Boswelan - No genuine use - Use of the mark in a clinical trial prior to filing an application for authorisation to place a medicinal product on the market - Proper reason for non-use - Concept)

(2019/C 305/09)

Language of the case: German

Parties

Appellant: Viridis Pharmaceutical Ltd. (represented by C. Spintig, S. Pietzcker and M. Prasse, Rechtsanwälte)

Other parties to the proceedings: European Union Intellectual Property Office (EUIPO) (represented by S. Hanne, acting as Agent), Hecht-Pharma GmbH (represented by J. Sachs and C. Sachs, Rechtsanwälte)

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Viridis Pharmaceutical Ltd to pay, in addition to its own costs, those incurred by the European Union Intellectual Property Office (EUIPO) and Hecht-Pharma GmbH. |

---

---

[Top](#document1)